Cipla Share News - Latest Updates, Live News & More

Latest news about Cipla

Cipla Shares Worth Rs. 51.05 Crores Traded in NSE Block Deal 3 days ago

Cipla experienced a significant block trade on the NSE, involving 331,705 shares at ₹1,539.10 per share, totaling ₹51.05 crores. This large-scale transaction highlights substantial investor interest in the pharmaceutical company. The impact on Cipla's stock price and trading patterns will be closely monitored by investors and analysts in the coming days.

Cipla USA Recalls Over 20,000 Packs of Asthma Medication Due to Stability Issues Aug 27, 2025

Cipla's Bommasandra Facility Receives VAI Classification from USFDA Aug 05, 2025

Cipla Secures ESG Rating of 60 from SEBI-Registered Provider Jul 29, 2025

Cipla Shares Surge 6% on Strong Quarterly Results, Brokerages Raise Target Prices Jul 28, 2025

More news about Cipla

28Jul 25

Cipla Shares Dip Despite Strong Q1 Performance and Record India Business

Cipla's Q1 consolidated net profit increased by 10% to ₹1,298.00 crore, surpassing analyst estimates. The India Business segment crossed ₹3,000.00 crore for the first time in an opening quarter, growing 6% year-on-year. North America business generated $226 million in quarterly revenue. Despite positive results, Cipla's shares fell 0.39% to ₹1,526.50. Revenue increased by 4.58% to ₹7,095.60 crore, while EBITDA grew 6.05% to ₹1,916.30 crore.

25Jul 25

Cipla Reports Strong Q1 FY26 Results, Eyes GLP-1 Market Expansion

Cipla Limited reported robust Q1 FY2026 results with total revenue of INR 6,957.47 crore, up 4% YoY. EBITDA reached INR 1,778.00 crore with a 25.6% margin, and net profit increased 10% YoY to INR 1,298.00 crore. Growth was seen across all major markets. The company plans to enter the GLP-1 market, aiming to launch Semaglutide upon patent expiry. With a strong cash reserve of INR 108.38 billion, Cipla is well-positioned for future investments and expansions.

25Jul 25

Cipla's Q1 Net Profit Surges 10% to ₹13 Billion, Beating Estimates

Cipla Limited reported strong Q1 financial results, with consolidated net profit rising 10% to ₹13.00 billion, surpassing analyst estimates. Revenue increased to ₹69.60 billion, and EBITDA grew to ₹17.78 billion. The 'One India' strategy achieved record Q1 sales exceeding ₹30.00 billion. Albuterol ranked No. 1 in North America with a 19.50% market share, while the South Africa private market grew at 1.5 times the market rate.

24Jul 25

Cipla Q1 Results Preview: Mixed Performance Expected with US Business Headwinds

Cipla Limited is expected to report mixed Q1 earnings on July 25. Revenue growth projections range from 3.6% to 9% YoY, driven by strong domestic sales but offset by declining US generics business. Net profit estimates range from ₹1,140.00 crore to ₹1,380.00 crore. US revenue is projected to decline 12-13% YoY due to lower gRevlimid prices, while domestic formulations segment is forecasted to grow 8-9% YoY. EBITDA margins are expected to contract by about 100 basis points YoY. Key focus areas include US business trajectory, pricing trends, India business recovery, new product launches, and cost management.

21Jul 25

Cipla Strengthens Respiratory Healthcare with ₹5 Crore Investment in Icaltech Innovations

Cipla Limited has announced a strategic investment of ₹5 crore to acquire a 20% stake in Icaltech Innovations Private Limited, a Bangalore-based medical devices company specializing in respiratory care diagnostics. The investment involves subscribing to 1,50,820 optionally convertible preference shares and 1 equity share. This move aims to strengthen Cipla's position in respiratory healthcare and expand its diagnostic solutions portfolio. The collaboration is expected to leverage synergies between Cipla's pharmaceutical expertise and Icaltech's medical device technologies. Icaltech has shown significant growth, with its turnover increasing from ₹1.28 crore in FY 2022-23 to ₹6.70 crore projected for FY 2024-25.

10Jul 25

Cipla Ltd. Shares in Focus: Block Trade Worth Rs. 61.27 Crores Executed

A block trade of 416,640 Cipla Ltd. shares was executed on the National Stock Exchange (NSE) at Rs. 1,470.60 per share, totaling Rs. 61.27 crores. This substantial transaction has drawn attention to the prominent Indian pharmaceutical company, potentially indicating strategic moves by large market players. While the parties involved remain undisclosed, such trades can sometimes signal shifts in institutional holdings or changing perspectives on the company's prospects.

26Jun 25

Cipla's Dividend Deadline: Last Day to Secure Rs 16 Per Share Payout

Cipla Ltd has declared a total dividend of Rs 16.00 per share, comprising a final dividend of Rs 13.00 and a special dividend of Rs 3.00. The last date to purchase shares and qualify for the dividend is June 26, with the record date set for June 27. The total dividend payout amounts to approximately Rs 1,292.00 crore, reflecting Cipla's strong financial position and commitment to shareholder returns.

02Jun 25

Cipla's Bengaluru Facility Receives One Observation in USFDA CGMP Inspection

Cipla Limited's manufacturing facility in Bommasandra, Bengaluru, underwent a Current Good Manufacturing Practices (CGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection concluded with the company receiving one observation in Form 483. While specific details of the observation were not disclosed, receiving only one observation is generally considered a positive outcome given the rigorous nature of USFDA inspections. Cipla is expected to address the observation and submit a response to the USFDA within the stipulated timeframe.

30May 25

Cipla's Bengaluru Facility Receives Single FDA Observation After Inspection

Cipla Ltd's Bengaluru facility underwent a cGMP inspection by the U.S. FDA from May 26-30, resulting in a Form 483 with one observation. The company has acknowledged the finding and committed to responding within the stipulated timeline, demonstrating their commitment to regulatory compliance.

30May 25

CIPLA's Bengaluru Facility Receives One FDA Observation After Inspection

The FDA conducted a CGMP inspection at CIPLA's manufacturing facility in Bommasandra, Bengaluru from May 26-30, 2025. The inspection concluded with one observation issued in Form 483. CIPLA will need to respond to the FDA with a plan to address the observation. The nature of the observation and its potential impact on operations have not been disclosed.

29May 25

Cipla Expands European Presence with New German Subsidiary

Cipla Limited has incorporated a new wholly owned subsidiary named 'Ciplarna GmbH' in Germany. This move is seen as a significant step to strengthen Cipla's presence in the European market, particularly in Germany, one of Europe's largest pharmaceutical markets. While specific details about the subsidiary's purpose and location are not yet disclosed, this establishment could potentially enhance Cipla's distribution network, facilitate regulatory processes, and explore R&D opportunities in Europe.

21May 25

Cipla's Abraxane Drug Launch Faces Stiff Competition from Chinese Firms

Cipla is facing unexpected challenges in launching its Abraxane drug due to competition from Chinese firms that have already secured FDA approvals and ANDAs. UBS reports this could reduce Cipla's earnings per share by 5.00%. The company's strategy to navigate this competitive landscape will be crucial for its market position and financial performance.

20May 25

CIPLA Invests in Green Energy: Acquires 26% Stake in AMPIN Energy for Solar Power Project

CIPLA has acquired a 26% stake in AMPIN Energy C&I Eighteen to develop a captive solar power project in Maharashtra. This investment aims to integrate renewable energy into CIPLA's operations, potentially reducing long-term energy costs, enhancing sustainability efforts, and improving energy security. The move aligns with the broader trend in the Indian pharmaceutical sector towards adopting green energy solutions.

14May 25

Cipla's Q4 Results Meet Expectations, FY26 EBITDA Margin Guidance Viewed as Conservative

Cipla reported strong Q4 results, meeting revenue and EBITDA estimates. The company's India business grew 8% YoY, while US revenue reached $221 million. For FY26, Cipla projects an EBITDA margin of 23.5-24.5%, which analysts view as conservative. The company exceeded its current year guidance by 150 basis points. Cipla is now focusing on EBITDA margin guidance rather than revenue targets, emphasizing profitability. Despite challenges like loss of exclusivity for generic Revlimid, Cipla expects continued growth. Analysts maintain a positive outlook with 'Buy' and 'Outperform' ratings.

13May 25

Cipla's Q4 Results: Revenue Beats Estimates, Profit Surges 30%; Warns of Future Margin Decline

Cipla's Q4 FY2023 results exceeded expectations with revenue up 9% to ₹6,729.69 crore and net profit rising 30% to ₹1,222.00 crore. EBITDA grew 17% to ₹1,538.00 crore, with margins improving to 22.80%. Despite strong performance, Cipla forecasts EBITDA margin declines to 23.5-24.5% in FY26 and a further 300 basis point drop in FY27, primarily due to the phasing out of gRevlimid. The company expects flat US business revenue in Q1 of the new fiscal year but projects continued topline growth.

12May 25

Cipla Ltd. Sets Date for Q4 and FY25 Results, Dividend Announcement

Cipla Ltd. has scheduled a board meeting for May 13, 2025, to review and approve Q4 and FY2025 financial results and consider a final dividend recommendation. The company has implemented a trading window closure from April 1 to May 15, 2025, to ensure fair trading practices. An earnings call is set for May 13, 2025, at 4:00 PM to discuss the results with investors and analysts.

09May 25

Cipla Ltd. Anticipates Mixed Q4 FY25 Results Amid Market Challenges

Cipla Ltd. is set to release Q4 FY25 results on May 13. Analysts project a 9.70% increase in net profit to Rs 1,023.10 crore. US operations face challenges due to Lanreotide supply issues and a weak respiratory season. India business expected to grow 9-10% year-over-year, boosted by Sanofi agreement. South African operations show strong performance due to Actor Pharma acquisition and tender sales recovery. FY25 EBITDA margins expected to align with 25.50% guidance, but concerns exist for FY26 margins.

21Mar 25

Cipla's Stock Set to Benefit from FTSE All World Index Weight Upgrade

Cipla, a leading Indian pharmaceutical company, has received a weight upgrade in the FTSE All World Index. This upgrade is projected to attract approximately $30.40 million (₹2.60 billion) in foreign investment inflows. The increased weighting is expected to enhance Cipla's visibility among global investors, potentially lead to increased passive fund inflows, and provide support to the stock price.

18Mar 25

Cipla Expands Dermatology Portfolio with Multi-Regional Licensing Deal

Cipla Limited has entered into a multi-regional licensing agreement with Formosa Pharmaceuticals for Clobetasol Propionate Topical Solution (Suspension). The deal primarily targets the United States market, with potential expansion to other territories. This strategic move aims to strengthen Cipla's presence in the global dermatology market, particularly in the competitive US sector. The agreement grants Cipla commercialization rights for the dermatological product, which is a potent corticosteroid used to treat various skin conditions.

21Feb 25

CIPLA's Subsidiary Sitec Labs Receives USFDA Observations; Company Secures Approval for Nilotinib Capsules

USFDA conducted a CGMP inspection at CIPLA's subsidiary Sitec Labs, issuing two Form 483 observations. CIPLA plans to address these promptly. Simultaneously, CIPLA received USFDA approval for Nilotinib Capsules, an oncology drug for chronic myeloid leukemia, with launch expected in FY 2025-26.

20Feb 25

Cipla Secures FDA Approval for Nilotinib Capsules, Eyes 2025-26 US Launch

Cipla Limited has received final USFDA approval for its New Drug Application for Nilotinib capsules in 50 mg, 150 mg, and 200 mg strengths. The drug is used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Cipla plans to launch the product in the US market during fiscal year 2025-26, strengthening its position in the oncology segment.